Memphasys
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 14 May 2021
- Reported shorts
- 9.1K
- Shares on issue
- 759.774M
Memphasys (MEM) Short Interest
Memphasys (ASX:MEM) had 0.00% of shares reported as short positions as of 14 May 2021, representing 9,064 shares. Memphasys operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Memphasys
Memphasys Limited specializes in advanced biological separations, focusing on reproductive biotechnology. The company leverages its proprietary technologies, Felix™ and RoXsta™, to enhance assisted reproductive treatments for both humans and animals. Memphasys is strategically positioned in the market with its innovative solutions aimed at bridging gaps in assisted reproductive technology.
Company profile →Memphasys (ASX:MEM) has 0.00% of its shares on issue reported as short positions as of 14 May 2021, or about 9,064 shares. Over the past 30 days that figure has been broadly flat, and over 7 days it has been broadly flat. MEM is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads MEM today
- Zanger BreakoutWatchScore 25rank 962 of 1942
- CAN SLIMWatchScore 10rank 1092 of 1541
- Minervini Trend TemplateWatchScore 17rank 1027 of 1716
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 10rank 1238 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
MEM fundamentals
In the year to 30 Jun 2026, Memphasys (ASX:MEM) recorded revenue of A$273.8K and a net loss after tax of A$4.1M. A year earlier it recorded revenue of A$3.7K and a net loss after tax of A$5.0M. Net margin −1,498.8% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest MEM news
All news- Notification regarding unquoted securities - MEM
asx · 13 Oct 2026
- Quarterly Activities/Appendix 4C Cash Flow Report
asx · 12 Oct 2026
- Initial Director's Interest Notice
asx · 5 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss MEM
Start a research thread or post the first pulse update